HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Oral semaglutide failed to slow Alzheimer's over 2 years in two phase III trials

Louis Nervegna · Dec 06, 2025 · ♥ 3 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Brain health & dementia
AI summary & key facts

Louis shares a MedPage Today report from CTAD that Alzheimer's patients on semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years versus placebo.

#glp1HD #alzheimersHD

Research cited

Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease annual meeting.

medpagetoday.comLink to medpagetoday.commedpagetoday.comNo photo description available.
← newer: A 92-year-old athlete's fitness mixes exercise benefit with older: Video post on statins, stroke and dementia with no readable →